tradingkey.logo
tradingkey.logo
Search

Acumen Pharmaceuticals Inc

ABOS
Add to Watchlist
2.920USD
+0.060+2.10%
Close 09-11 16:00ET
211.88MMarket Cap
LossP/E TTM

ABOS Income Statement

You can find the annual or quarterly income statement of Acumen Pharmaceuticals Inc here for insights into the performance and operational efficiency of Acumen Pharmaceuticals Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
Total revenue
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
--329.00K
--730.00K
--151.00K
--226.00K
Revenue
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
--329.00K
--730.00K
--151.00K
--226.00K
Operating expenses
-22.02%32.56M
-30.36%21.15M
-36.36%25.20M
-17.83%26.51M
71.24%41.75M
70.87%30.37M
114.20%39.60M
101.17%32.27M
80.89%24.38M
35.32%17.77M
29.74%18.49M
41.05%16.04M
29.46%13.48M
42.68%13.13M
69.32%14.25M
188.97%11.37M
202.56%10.41M
142.71%9.21M
403.89%8.41M
22.20%3.94M
57.41%3.44M
66.95%3.79M
--1.67M
--3.22M
--2.19M
--2.27M
R&D expenses
-25.09%27.81M
-34.76%16.48M
-40.62%20.53M
-19.37%21.97M
90.06%37.13M
102.96%25.27M
160.05%34.57M
143.73%27.25M
113.87%19.53M
42.88%12.45M
23.70%13.29M
34.54%11.18M
24.75%9.13M
45.58%8.71M
89.42%10.75M
361.61%8.31M
224.80%7.32M
132.16%5.99M
452.92%5.67M
-39.88%1.80M
16.97%2.25M
25.76%2.58M
--1.03M
--2.99M
--1.93M
--2.05M
Depreciation, depletion, and amortization
-31.25%11.00K
-73.33%12.00K
-72.73%12.00K
-66.67%15.00K
-64.44%16.00K
2.27%45.00K
12.82%44.00K
12.50%45.00K
-15.09%45.00K
-15.38%44.00K
-20.41%39.00K
-9.09%40.00K
35.90%53.00K
40.54%52.00K
1533.33%49.00K
4300.00%44.00K
--39.00K
--37.00K
--3.00K
--1.00K
--0.00
--0.00
--0.00
----
--0.00
--0.00
Operating profit
22.02%-32.56M
30.36%-21.15M
36.36%-25.20M
17.83%-26.51M
-71.24%-41.75M
-70.87%-30.37M
-114.20%-39.60M
-101.17%-32.27M
-80.89%-24.38M
-35.32%-17.77M
-29.74%-18.49M
-41.05%-16.04M
-29.46%-13.48M
-42.68%-13.13M
-69.32%-14.25M
-188.97%-11.37M
-202.56%-10.41M
-142.71%-9.21M
-527.52%-8.41M
-58.03%-3.94M
-69.09%-3.44M
-85.39%-3.79M
---1.34M
---2.49M
---2.04M
---2.05M
Net non-operating interest income (expenses)
Non-operating interest income
-44.86%1.11M
-56.94%1.06M
-55.82%1.32M
-53.22%1.64M
-47.20%2.02M
-38.30%2.47M
-24.27%2.99M
12.16%3.50M
102.55%3.82M
118.61%4.00M
183.84%3.95M
371.19%3.12M
624.62%1.88M
2310.53%1.83M
2145.16%1.39M
1691.89%663.00K
6400.00%260.00K
1800.00%76.00K
--62.00K
--37.00K
--4.00K
300.00%4.00K
--0.00
--0.00
--0.00
--1.00K
Non-operating interest expense
0.00%732.00K
-0.14%723.00K
-27.97%747.00K
-28.04%739.00K
-27.09%732.00K
-27.60%724.00K
78.49%1.04M
--1.03M
--1.00M
--1.00M
--581.00K
----
----
----
----
----
----
----
----
--23.00K
----
----
----
--0.00
----
----
Gains from sale of securities
-15.29%-362.00K
-15.72%-346.00K
---340.00K
---329.00K
---314.00K
---299.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Special income (expenses)
-300.00%-160.00K
142.11%460.00K
-130.91%-170.00K
-4300.00%-440.00K
-103.64%-40.00K
480.00%190.00K
140.44%550.00K
---10.00K
--1.10M
---50.00K
---1.36M
----
----
----
--0.00
--0.00
100.00%0.00
100.00%0.00
-100.00%0.00
--0.00
---57.94M
---23.22M
--586.00K
--0.00
--0.00
--0.00
Other non-operating income (expenses)
85.27%-19.00K
32.81%-43.00K
93.55%-4.00K
-309.09%-69.00K
-89.71%-129.00K
-18.52%-64.00K
-195.24%-62.00K
178.57%33.00K
-325.00%-68.00K
-1250.00%-54.00K
-110.00%-21.00K
-2000.00%-42.00K
---16.00K
-500.00%-4.00K
-350.00%-10.00K
-110.53%-2.00K
-100.00%0.00
-88.89%1.00K
--4.00K
--19.00K
--19.00K
--9.00K
--0.00
--0.00
--0.00
--0.00
Income before tax
20.10%-32.72M
27.99%-20.74M
32.34%-25.14M
11.13%-26.45M
-99.40%-40.95M
-93.61%-28.80M
-125.22%-37.15M
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-28.22%-16.50M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
-54.10%-12.87M
-174.47%-10.71M
83.46%-10.15M
66.19%-9.13M
-1005.83%-8.35M
-56.71%-3.90M
-2915.14%-61.36M
-1220.15%-27.00M
---755.00K
---2.49M
---2.04M
---2.04M
Income tax
----
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
20.10%-32.72M
27.99%-20.74M
32.34%-25.14M
11.13%-26.45M
-99.40%-40.95M
-93.61%-28.80M
-125.22%-37.15M
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-28.22%-16.50M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
-54.10%-12.87M
-174.47%-10.71M
83.46%-10.15M
66.19%-9.13M
-1005.83%-8.35M
-56.71%-3.90M
-2915.14%-61.36M
-1220.15%-27.00M
---755.00K
---2.49M
---2.04M
---2.04M
Net income from continuous operations
20.10%-32.72M
27.99%-20.74M
32.34%-25.14M
11.13%-26.45M
-99.40%-40.95M
-93.61%-28.80M
-125.22%-37.15M
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-28.22%-16.50M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
-54.10%-12.87M
-174.47%-10.71M
83.46%-10.15M
66.19%-9.13M
-1005.83%-8.35M
-56.71%-3.90M
-2915.14%-61.36M
-1220.15%-27.00M
---755.00K
---2.49M
---2.04M
---2.04M
Net income attributable to controlling interests
20.10%-32.72M
27.99%-20.74M
32.34%-25.14M
11.13%-26.45M
-99.40%-40.95M
-93.61%-28.80M
-125.22%-37.15M
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-28.22%-16.50M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
-54.10%-12.87M
-174.47%-10.71M
83.46%-10.15M
66.19%-9.13M
-1005.83%-8.35M
-56.71%-3.90M
-2915.14%-61.36M
-1220.15%-27.00M
---755.00K
---2.49M
---2.04M
---2.04M
Net income attributable to common shareholders
20.10%-32.72M
27.99%-20.74M
32.34%-25.14M
11.13%-26.45M
-99.40%-40.95M
-93.61%-28.80M
-125.22%-37.15M
-129.72%-29.77M
-76.89%-20.54M
-31.54%-14.87M
-28.22%-16.50M
-20.98%-12.96M
-14.37%-11.61M
-23.86%-11.31M
-54.10%-12.87M
-174.47%-10.71M
83.46%-10.15M
66.19%-9.13M
-1005.83%-8.35M
-56.71%-3.90M
-2915.14%-61.36M
-1220.15%-27.00M
---755.00K
---2.49M
---2.04M
---2.04M
Basic earnings per share
33.02%-0.45
31.05%-0.33
32.89%-0.41
11.86%-0.44
-97.77%-0.68
-91.33%-0.48
-117.46%-0.62
-107.35%-0.50
-20.79%-0.34
9.78%-0.25
9.53%-0.28
9.64%-0.24
-12.90%-0.28
-22.19%-0.28
24.49%-0.31
-159.32%-0.26
84.21%-0.25
67.71%-0.23
-2031.34%-0.42
-58.29%-0.10
-2915.12%-1.59
-1220.11%-0.70
---0.02
---0.06
---0.05
---0.05
Diluted earnings per share
33.02%-0.45
31.05%-0.33
32.89%-0.41
11.86%-0.44
-97.77%-0.68
-91.33%-0.48
-117.46%-0.62
-107.35%-0.50
-20.79%-0.34
9.78%-0.25
9.53%-0.28
9.64%-0.24
-12.90%-0.28
-22.19%-0.28
24.49%-0.31
-159.32%-0.26
84.21%-0.25
67.71%-0.23
-2031.34%-0.42
-58.29%-0.10
-2915.12%-1.59
-1220.11%-0.70
---0.02
---0.06
---0.05
---0.05
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Acumen Pharmaceuticals Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing ABOS stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Acumen Pharmaceuticals Inc's net income for the year?

Acumen Pharmaceuticals Inc posted -121.33M in net income for fiscal year 2025.

How much net income did Acumen Pharmaceuticals Inc post in the last quarter?

Acumen Pharmaceuticals Inc reported -32.72M in net income for the latest quarter。

What was Acumen Pharmaceuticals Inc's annual operating profit?

Acumen Pharmaceuticals Inc's operating income was -123.83M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.